Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Star Lake Bioscience Co's Revenue for the
three
months ended in Mar. 2026 was ¥3,740 Mil. Star Lake Bioscience Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was ¥720 Mil.
Hence, Star Lake Bioscience Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 5.20.
Star Lake Bioscience Co (SHSE:600866) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Star Lake Bioscience Co Receivables Turnover Related Terms
Star Lake Bioscience Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Star Lake Bioscience Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Lake Bioscience Co Receivables Turnover Chart
SHSE:600866 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Star Lake Bioscience Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Lake Bioscience Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Star Lake Bioscience Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Star Lake Bioscience Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Lake Bioscience Co (SHSE:600866) has a Receivables Turnover of 5.20 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Star Lake Bioscience Co and its competitors. According to the industry distribution chart, Star Lake Bioscience Co ranks #68 out of 843 companies in the Biotechnology industry, placing it in the top 8.1%.
Is Star Lake Bioscience Co's Receivables Turnover too high?
Star Lake Bioscience Co's current Receivables Turnover is 5.20. The Biotechnology industry median Receivables Turnover is 5.27. Star Lake Bioscience Co's value of 5.20 is 1.3% below this industry median. Based on the distribution chart, Star Lake Bioscience Co ranks #68 out of 843 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Star Lake Bioscience Co has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Star Lake Bioscience Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Star Lake Bioscience Co ranks #68 out of 843 companies for Receivables Turnover. This places Star Lake Bioscience Co in the top 8% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. Star Lake Bioscience Co's value of 5.20 is 1.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Lake Bioscience Co's current Receivables Turnover of 5.20 is 1.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Star Lake Bioscience Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Lake Bioscience Co's current Receivables Turnover is 5.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Lake Bioscience Co stock overvalued right now?
Based on GuruFocus' analysis, Star Lake Bioscience Co (SHSE:600866) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.90, compared to a current price of ¥4.30 — trading 27.1% below its estimated fair value. The current Receivables Turnover is 5.20 and 1.3% below the Biotechnology industry median of 5.27. Star Lake Bioscience Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Star Lake Bioscience Co (SHSE:600866), the current Receivables Turnover is 5.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Lake Bioscience Co (SHSE:600866) Overvalued in 2026?
Based on GuruFocus' analysis, Star Lake Bioscience Co stock appears to be undervalued.
The current stock price of ¥4.30 is trading 27.1% below its estimated GF Value™ of ¥5.90.
GuruFocus considers Star Lake Bioscience Co to be Modestly Undervalued.
Key valuation signals for SHSE:600866:
Receivables Turnover: 5.20
GF Value™: ¥5.90 vs. price of ¥4.30 (27.1% below fair value)
Industry Position: 1.3% below the Biotechnology median (#68 of 843)
No single metric tells the full story. See the SHSE:600866 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Lake Bioscience Co Inc is a China-based Pharmaceutical manufacturer. The company is mainly engaged in the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates. Products offered by the company include proline, guanosine, adenosine, adenine, adefovir dipivoxil, memantine hydrochloride, Proline, threonine, lysine, among others. Its products are used in food processing, feed processing, and pharmaceutical manufacturing. Star Lake sells its products through direct sales and distributors in China and overseas markets.
67GF Score
Get the complete analysis for SHSE:600866
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600866 has been successfully added to your 
